/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC" or the "Company") (NYSE: ADCT). Such investors are...
/PRNewswire/ -- Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023,...
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 7.50% and 5.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financial results for the first quarter 2023 and...
ADC Therapeutics SA (ADCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
/PRNewswire/ -- PharmaVentures announces its new office in Korea as part of its continued strategic expansion Headquartered in London, UK, PharmaVentures has...
Seres Therapeutics (MCRB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...
ADC Therapeutics SA (NYSE: ADCT) today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2022, has been filed with the U.S. Securities and Exchange Commission (the “SEC”)....